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IntroductionSoft-tissue sarcomas (STS) constitute an uncommon and heterogeneous group of tumors of mesenchymal origin, they share several clinical and pathological features and are usually considered as a group for diagnostic and therapeutic purposes, 
with the exception of specific particularities of some subtypes [1]. Alveolar soft-part sarcoma (ASPS) is a rare, distinctive sarcoma, 
typically occurring in young patients. Although it displays a relatively indolent clinical course, the ultimate prognosis is poor 
and is often characterized by late metastases [2]. In advanced cases, with multiple metastatic involvement and recurrent cases, only 
palliative treatment is preferred due to its bad prognosis [3]. 
 
We describe our experience treating a patients with ASPS with 
metastatic disease using tyrosine kinase inhibitor (sunitinib) with 
an outstanding survival and quality of life. 
Case
This 23-year-old man with unremarkable past medical history was seen in our clinic with a history of 2 years of increasing rectal 
pain associated with swelling in his right leg, and subsequently 
rectal bleeding with mild diarrhea. On physical examination he was 
found to have a very important skin in duration besides the anus, and at the digital rectal examination a 5cm mass was found at the 
anal verge.
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Alveolar soft-part sarcoma is a rare malignant entity with poor prognosis. Chemotherapy has limited activity in this type of sarcoma, we 
describe here the outcomes of the first case documented in our Institution with metastatic disease, treated exclusively with sunitinib.
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Figure 1: Alveolar soft-part sarcoma hematoxilyn-eosin staining. Nest of cells, composed of large polygonal cells.
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Figure 2: PAS staining, at 40X.
A Thorax-Abdomen and Pelvis CT Scan was performed, and 
showed: Many pulmonary nodules distributed diffusely with 
diameters up to 25 mm, compatible with metastatic disease. And also was reported a solid, heterogeneous pelvic mass with well 
defined borders, approximately 75 mm in maximum diameter, with 
gas present inside suggesting a fistulous process, with infiltration of the anal canal, as well as the anus elevator muscle in its left 
portion. Colonoscopy showed an indurated lesion in the perianal 
region. A biopsy of the lesion was taken in the operating room. 
The biopsy showed a malignant neoplasm with well defined nests 
of cells separated by fibrous stroma, composed of large polygonal 
cells with prominent nucleoli, with alveolar patter tumor cells. 
Overall features were suggestive of ASPS. Many of the cells were 
periodic acid Schiff (PAS)–positive. The cells were negative for pan-
cytokeratin, chromogranin, synaptophysin, PLAP, EMA, myoglobin, 
myogenin, caldesmon, S-100, melan A, CD34, Factor VIII y LCA. The 
cells were strongly positive for desmin and actin (focally) (Figures 
1 & 2).
Treatment
Because the patient was diagnosed with a stage IV ASPS the case 
was discussed at the multidisciplinary tumor board, and a tyrosine 
kinase inhibitor was recommended; in this case, oral sunitinib was 
started at a dose of 50 mg daily 4 weeks on2 weeks off.
Outcome and Follow-up
The patient still on sunitinib treatment, he has at this time 3 
years and 6 months with no evidence of progression. During the 
first year of treatment CT Scans showed a reduction of the number and size of the pulmonary nodules, as well as the pelvic disease 
of about 50% (partial response). At the end of the first year of 
treatment, a bone scan showed 2 new lesions: Right iliac bone and 
body of L3 (considered new lesions). Taking into account that the patient had response in lungs and pelvic disease, the new lesions 
could be considered “oligo-progression” we decided to continue 
the TKI and give palliative external radiotherapy to bone lesions. 
(20Gy). Two years after this therapy, the patient continues with 
stable disease. He has an outstanding quality of life really, with no 
important side effects and actually he got married recently.
Side Effects and Tolerance to the Treatment
Sunitinib was well tolerated by the patient. The side effects presented were: hair color change and hypothyroidism (the patient 
is receiving thyroid hormone supplementation).
Discussion
ASPS is a rare tumor and accounts for 0.5–0.9% of all soft tissue 
sarcomas [4]. ASPS comprise only 1% of all soft tissue sarcomas [5]. The tumor typically occurs in the deep soft tissues, most often in 
the buttock and thigh, with a smaller number of cases at other soft-tissue locations such as the arm, chest and retroperitoneal tissues 
[6]. Studies on the large series from the MD Anderson Cancer Center, 
Texas, USA, found a 5-year disease-free survival of 71% in patients 
presenting with localized disease as compared with only 20% in 
patients presenting with metastases [7]. ASPS are characterized 
by uniform, organoid nests of polygonal tumor cells, separated by 
fibro vascular septa and delicate capillary-sized vascular channels. 
In these nests there is prominent cellular dyscohesion, leading 
to the distinctive pseudo alveolar pattern for which it is named. 
A characteristic finding is the presence of periodic acid-Schiff-
positive [8]. Immuno histo chemical analysis played a limited part 
in the diagnosis of ASPS. Lung metastasis are very common (42–
65%) but also brain and bone metastasis have been described. The 
treatment of ASPS is surgery (when the disease is localizaed), but in the metastatic setting, the activity of antiangiogenic agents such as 
INF-a [9] bevacizumab [10], sunitinib [11], and cediranib [12] have 
been used in ASPS. 
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